<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04120090</url>
  </required_header>
  <id_info>
    <org_study_id>Ruxolitinib-HLH</org_study_id>
    <nct_id>NCT04120090</nct_id>
  </id_info>
  <brief_title>Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis</brief_title>
  <official_title>Clinical Study of Different Doses of Ruxolitinib as a Salvage Therapy for Refractory/Relapsed Hemophagocytic Lymphohistiocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to investigate the efficacy and safety of different doses of ruxolitinib as
      a salvage therapy for refractory/relapsed hemophagocytic lymphohistiocytosis(HLH).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>1 years</time_frame>
    <description>complete response (CR) and partial response (PR) rates</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>1 years</time_frame>
    <description>from date of inclusion to date of progression, relapse, or death from any cause Overall Survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 years</time_frame>
    <description>from the date of inclusion to date of death, irrespective of cause Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Adverse events including myelosuppression, infection, bleeding and so on.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hemophagocytic Lymphohistiocytosis</condition>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose ruxolitinib</intervention_name>
    <description>The dose for adult patients(Age&gt;=14 years) is generally 10 mg twice daily. For children(Age&lt;14 years ,weight &gt;=25kg),the dose was generally 5mg twice daily. For children(Age&lt;14 years, weight &lt;25kg), the dose was generally 2.5mg twice daily.</description>
    <arm_group_label>Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose ruxolitinib</intervention_name>
    <description>The dose for adult patients(Age&gt;=14 years) is generally 20mg twice daily. For children(Age&lt;14 years ,weight &gt;=25kg),the dose was generally 10mg twice daily. For children(Age&lt;14 years, weight &lt;25kg), the dose was generally 5mg twice daily</description>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. meet hemophagocytic lymphohistiocytosis (HLH)-04 diagnostic criteria;

          2. treated with HLH-94 no less than 2 weeks before enrollment and did not achieve at
             least PR; or relapsed patients after remission；

          3. Life expectancy exceeds 1 month;

          4. Age≥1 year old and ≤75 years old, gender is not limited；

          5. Before the start of the study, total bilirubin ≤ 10 times the upper limit of normal;
             serum creatinine ≤ 1.5 times normal；

          6. Serum human immunodeficiency virus(HIV) antigen or antibody negative；

          7. Hepatitis C virus (HCV) antibody is negative, or HCV antibody is positive, but HCV RNA
             is negative；

          8. Both hepatitis B virus (HBV) surface antigen and HBV core antibody were negative. If
             any of the above is positive, peripheral blood hepatitis B virus DNA titer should be
             detected, and less than 1×103 copies/ml can enter the group；

          9. Informed consent.

        Exclusion Criteria:

          1. Pregnancy or lactating Women；

          2. Allergic to ruxolitinib；

          3. Active bleeding of the internal organs；

          4. uncontrollable infection；

          5. Serious mental illness;

          6. Non-melanoma skin cancer history;

          7. Patients unable to comply during the trial and/or follow-up phase;

          8. Participate in other clinical research at the same time.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>jingshi wang</last_name>
    <phone>86-010-63139862</phone>
    <email>wangjingshi987@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhao wang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 6, 2019</study_first_submitted>
  <study_first_submitted_qc>October 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2019</study_first_posted>
  <last_update_submitted>October 27, 2019</last_update_submitted>
  <last_update_submitted_qc>October 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Wang</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

